Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

Madeleine S Q Kortenhorst, Michel D. Wissing, Ronald Rodriguez, Sushant K. Kachhap, Judith J M Jans, Petra van der Groep, Henk M W Verheul, Anuj Gupta, Paul O. Aiyetan, Elsken van der Wall, Michael A. Carducci, Paul J. Van Diest, Luigi Marchionni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Histone deacetylases (HDACs) have emerged as important targets for cancer treatment. HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL). To improve the clinical benefit of HDAC is in solid tumors, combination strategies with HDACis could be employed. In this study, we applied Analysis of Functional Annotation (AFA) to provide a comprehensive list of genes and pathways affected upon HDACi-treatment in prostate cancer cells. This approach provides an unbiased and objective approach to high throughput data mining. By performing AFA on gene expression data from prostate cancer cell lines DU-145 (an HDACi-sensitive cell line) and PC 3 (a relatively HDACi-resistant cell line) treated with HDACis valproic acid or vorinostat, we identified biological processes that are affected by HDACis and are therefore potential treatment targets for combination therapy. Our analysis revealed that HDAC-inhibition resulted among others in upregulation of major histocompatibility complex (MHC) genes and deregulation of the mitotic spindle checkpoint by downregulation of genes involved in mitosis. These findings were confirmed by AFA on publicly available data sets from HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays with HDACi treated and non-treated (control) prostate cancer cells. All results from this extensive analysis are provided as an online research source (available at the journal's website and at http://luigimarchionni.org/HDACIs.html). By publishing this data, we aim to enhance our understanding of the cellular changes after HDAC-inhibition, and to identify novel potential combination strategies with HDACis for the treatment of prostate cancer patients.

Original languageEnglish (US)
Pages (from-to)907-920
Number of pages14
JournalEpigenetics
Volume8
Issue number9
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Prostatic Neoplasms
Histone Deacetylases
Cell Line
Therapeutics
M Phase Cell Cycle Checkpoints
Genes
Biological Phenomena
Cutaneous T-Cell Lymphoma
Data Mining
Valproic Acid
Major Histocompatibility Complex
Mitosis
Neoplasms
Up-Regulation
Down-Regulation
Gene Expression

Keywords

  • Analysis of functional annotation
  • Gene expression analysis
  • HDACis
  • Major histocompatibility complex
  • Mitotic spindle checkpoint
  • Prostate cancer
  • Valproic acid
  • Vorinostat

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Kortenhorst, M. S. Q., Wissing, M. D., Rodriguez, R., Kachhap, S. K., Jans, J. J. M., van der Groep, P., ... Marchionni, L. (2013). Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics, 8(9), 907-920. https://doi.org/10.4161/epi.25574

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. / Kortenhorst, Madeleine S Q; Wissing, Michel D.; Rodriguez, Ronald; Kachhap, Sushant K.; Jans, Judith J M; van der Groep, Petra; Verheul, Henk M W; Gupta, Anuj; Aiyetan, Paul O.; van der Wall, Elsken; Carducci, Michael A.; Van Diest, Paul J.; Marchionni, Luigi.

In: Epigenetics, Vol. 8, No. 9, 09.2013, p. 907-920.

Research output: Contribution to journalArticle

Kortenhorst, MSQ, Wissing, MD, Rodriguez, R, Kachhap, SK, Jans, JJM, van der Groep, P, Verheul, HMW, Gupta, A, Aiyetan, PO, van der Wall, E, Carducci, MA, Van Diest, PJ & Marchionni, L 2013, 'Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors', Epigenetics, vol. 8, no. 9, pp. 907-920. https://doi.org/10.4161/epi.25574
Kortenhorst, Madeleine S Q ; Wissing, Michel D. ; Rodriguez, Ronald ; Kachhap, Sushant K. ; Jans, Judith J M ; van der Groep, Petra ; Verheul, Henk M W ; Gupta, Anuj ; Aiyetan, Paul O. ; van der Wall, Elsken ; Carducci, Michael A. ; Van Diest, Paul J. ; Marchionni, Luigi. / Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. In: Epigenetics. 2013 ; Vol. 8, No. 9. pp. 907-920.
@article{ddac2017d5de42a4b2b9b7cbd1593db3,
title = "Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors",
abstract = "Histone deacetylases (HDACs) have emerged as important targets for cancer treatment. HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL). To improve the clinical benefit of HDAC is in solid tumors, combination strategies with HDACis could be employed. In this study, we applied Analysis of Functional Annotation (AFA) to provide a comprehensive list of genes and pathways affected upon HDACi-treatment in prostate cancer cells. This approach provides an unbiased and objective approach to high throughput data mining. By performing AFA on gene expression data from prostate cancer cell lines DU-145 (an HDACi-sensitive cell line) and PC 3 (a relatively HDACi-resistant cell line) treated with HDACis valproic acid or vorinostat, we identified biological processes that are affected by HDACis and are therefore potential treatment targets for combination therapy. Our analysis revealed that HDAC-inhibition resulted among others in upregulation of major histocompatibility complex (MHC) genes and deregulation of the mitotic spindle checkpoint by downregulation of genes involved in mitosis. These findings were confirmed by AFA on publicly available data sets from HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays with HDACi treated and non-treated (control) prostate cancer cells. All results from this extensive analysis are provided as an online research source (available at the journal's website and at http://luigimarchionni.org/HDACIs.html). By publishing this data, we aim to enhance our understanding of the cellular changes after HDAC-inhibition, and to identify novel potential combination strategies with HDACis for the treatment of prostate cancer patients.",
keywords = "Analysis of functional annotation, Gene expression analysis, HDACis, Major histocompatibility complex, Mitotic spindle checkpoint, Prostate cancer, Valproic acid, Vorinostat",
author = "Kortenhorst, {Madeleine S Q} and Wissing, {Michel D.} and Ronald Rodriguez and Kachhap, {Sushant K.} and Jans, {Judith J M} and {van der Groep}, Petra and Verheul, {Henk M W} and Anuj Gupta and Aiyetan, {Paul O.} and {van der Wall}, Elsken and Carducci, {Michael A.} and {Van Diest}, {Paul J.} and Luigi Marchionni",
year = "2013",
month = "9",
doi = "10.4161/epi.25574",
language = "English (US)",
volume = "8",
pages = "907--920",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors

AU - Kortenhorst, Madeleine S Q

AU - Wissing, Michel D.

AU - Rodriguez, Ronald

AU - Kachhap, Sushant K.

AU - Jans, Judith J M

AU - van der Groep, Petra

AU - Verheul, Henk M W

AU - Gupta, Anuj

AU - Aiyetan, Paul O.

AU - van der Wall, Elsken

AU - Carducci, Michael A.

AU - Van Diest, Paul J.

AU - Marchionni, Luigi

PY - 2013/9

Y1 - 2013/9

N2 - Histone deacetylases (HDACs) have emerged as important targets for cancer treatment. HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL). To improve the clinical benefit of HDAC is in solid tumors, combination strategies with HDACis could be employed. In this study, we applied Analysis of Functional Annotation (AFA) to provide a comprehensive list of genes and pathways affected upon HDACi-treatment in prostate cancer cells. This approach provides an unbiased and objective approach to high throughput data mining. By performing AFA on gene expression data from prostate cancer cell lines DU-145 (an HDACi-sensitive cell line) and PC 3 (a relatively HDACi-resistant cell line) treated with HDACis valproic acid or vorinostat, we identified biological processes that are affected by HDACis and are therefore potential treatment targets for combination therapy. Our analysis revealed that HDAC-inhibition resulted among others in upregulation of major histocompatibility complex (MHC) genes and deregulation of the mitotic spindle checkpoint by downregulation of genes involved in mitosis. These findings were confirmed by AFA on publicly available data sets from HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays with HDACi treated and non-treated (control) prostate cancer cells. All results from this extensive analysis are provided as an online research source (available at the journal's website and at http://luigimarchionni.org/HDACIs.html). By publishing this data, we aim to enhance our understanding of the cellular changes after HDAC-inhibition, and to identify novel potential combination strategies with HDACis for the treatment of prostate cancer patients.

AB - Histone deacetylases (HDACs) have emerged as important targets for cancer treatment. HDAC-inhibitors (HDACis) are well tolerated in patients and have been approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL). To improve the clinical benefit of HDAC is in solid tumors, combination strategies with HDACis could be employed. In this study, we applied Analysis of Functional Annotation (AFA) to provide a comprehensive list of genes and pathways affected upon HDACi-treatment in prostate cancer cells. This approach provides an unbiased and objective approach to high throughput data mining. By performing AFA on gene expression data from prostate cancer cell lines DU-145 (an HDACi-sensitive cell line) and PC 3 (a relatively HDACi-resistant cell line) treated with HDACis valproic acid or vorinostat, we identified biological processes that are affected by HDACis and are therefore potential treatment targets for combination therapy. Our analysis revealed that HDAC-inhibition resulted among others in upregulation of major histocompatibility complex (MHC) genes and deregulation of the mitotic spindle checkpoint by downregulation of genes involved in mitosis. These findings were confirmed by AFA on publicly available data sets from HDACi-treated prostate cancer cells. In total, we analyzed 375 microarrays with HDACi treated and non-treated (control) prostate cancer cells. All results from this extensive analysis are provided as an online research source (available at the journal's website and at http://luigimarchionni.org/HDACIs.html). By publishing this data, we aim to enhance our understanding of the cellular changes after HDAC-inhibition, and to identify novel potential combination strategies with HDACis for the treatment of prostate cancer patients.

KW - Analysis of functional annotation

KW - Gene expression analysis

KW - HDACis

KW - Major histocompatibility complex

KW - Mitotic spindle checkpoint

KW - Prostate cancer

KW - Valproic acid

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=84883529774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883529774&partnerID=8YFLogxK

U2 - 10.4161/epi.25574

DO - 10.4161/epi.25574

M3 - Article

C2 - 23880963

AN - SCOPUS:84883529774

VL - 8

SP - 907

EP - 920

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 9

ER -